Yüklüyor......
Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
Bevacizumab plus chemotherapy was approved by the US Food and Drug Administration (FDA) as a first-line treatment for advanced nonsquamous, non-small-cell lung cancer (NSCLC) in 2006. This study retrospectively compared the efficacy of bevacizumab plus chemotherapy with chemotherapy alone as the fir...
Kaydedildi:
| Yayımlandı: | Onco Targets Ther |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4973774/ https://ncbi.nlm.nih.gov/pubmed/27536131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S110339 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|